Back to top
more

Cassava Sciences (SAVA)

(Delayed Data from NSDQ)

$26.21 USD

26.21
1,382,005

+0.41 (1.57%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $26.12 -0.09 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.

Company News for Sep 30, 2024

Companies In The Article Are:BMY, SAVA, SATS, COST

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

Ekta Bagri headshot

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.

Sanghamitra Saha headshot

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

Brian Bolan headshot

Brian's Big Idea on Low Priced Stocks

A look at low priced stocks and the Stocks Under $10 Service.

Cassava (SAVA) Up on Progress With Alzheimers Disease Study

Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.

Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $34.31, moving +0.7% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $35.92, moving -1.48% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

Cassava Sciences, Inc. (SAVA) closed at $35.64 in the latest trading session, marking a -1.87% move from the prior day.

Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $43.07, moving -1.76% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $31.04, moving -1.71% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $21.72, marking a +0.14% move from the previous day.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.

Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.

Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $38.47, moving +1.37% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed at $40.17 in the latest trading session, marking a -1.62% move from the prior day.